Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Fabtech Technologies Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹191
Per ShareLot Size
75 Shares
Minimum Investment
₹14,325
Issue Size
₹230.35 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
94.61%
Promoter Holding (Post-Issue)
68.94%
Issue Type
Book Building
ISIN
INE0HF201011
We are a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. (Source: CRISIL Report). We offer services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies. In such projects we offer end to end turnkey engineering services which range from disease identification until installation and commissioning of equipment. Additionally, we also offer some of our engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. Our Company has adopted an asset light approach wherein we procure key equipment and materials for our projects from Related Entities to ensure that our projects are executed efficiently, to integrate our project execution operations and to reduce our dependence on third party suppliers. Our comprehensive solutions encompasses the entire project lifecycle of our customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. In addition to offering targeted solutions across the value chain, we also have an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. Our footprint spans more than 62 countries globally and across regions including but not limited to, Middle East, Africa, Asia, Europe, Latin America, North America, etc. (Source: CRISIL Report). Since incorporation and till July 31, 2025, our Company has completed fifty one (51) projects across countries, namely Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, United Arab Emirates.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 1,20,60,000 equity shares of face value of Rs. 10 each ("Equity Shares") of the company for cash at a price of Rs. 191 per equity share (Including a Share Premium of Rs. 181 Per Equity Share) ("Issue Price") aggregating to Rs. 2302.97 crores( '' Issue"" ). ( The issue Shall Constitute 27.13% of the post-issue paid-up equity share capital of the company. The issue includes a reservation of 54,945 equity shares of face value of Rs. 10 each, aggregating to Rs. 1.00 crores (Constituting 0.12% of the Post Issue Paid-up Equity Share Capital of the Company) for subscription by eligible employees (the " Employee Reservation Portion " ). the issue less the employees reservation portion is hereinafter referred to as the " Net Issue ". the issue and the net issue 27.13% and 27.01% respectively, of the post-issue paid-up equity share capital of the company. the company in consultation with the book running lead Manager , may offered a discount of 4.71% (Equivalent of Rs. 9 Per Equity Share) on the issue price to eligible employees bidding under the employee reservation portion ( " Employee Discount " ). Price Band: Rs. 181/- to Rs. 191/- for equity share of face value of Rs. 10 each. The floor price is 18.10 times times the face value and cap price is 19.10 times of the face value of the equity shares. Bids can made for a minimum of 75 equity shares and in multiples of 75 equity shares thereafter. A discount of Rs. 9 per equity share is being offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Cumulative capex in global pharmaceuticals industry was ~$ 370-420 billion over 2020 to 2024. During this period, capex of pharmaceuticals companies as a percentage of their revenue remained between 5.0-6.0%. However, analysis of regional capex trends reveals that the capex activities are dependent on industry dynamics as well as policy frameworks across different regions. Capex activities are also dependent on the maturity of market in terms of penetration of different medicines. In the growth stage some of the emerging markets like Latin- America and Caribbean and Asia- Pacific have seen higher capex spends compared to matured markets like the US, Europe and Canada. Global pharmaceutical capex is estimated to increase 1.3x and witness cumulative capex investments of $500-550 billion between 2025-2029 owing to sustained capex investments due to expiration of patents, increasing generic medicines usage and pricing pressures. Governments of the UAE and the KSA are increasingly focusing on local manufacturing of pharmaceuticals, which is expected to, consequently, increase capex in the space. In 2017, Pfizer Global Supply completed the construction of a new manufacturing facility in King Abdullah Economic City. The site - the first for Pfizer in the KSA will allow patients in the country to access Pfizer medicines such as Lipitor (atorvastatin calcium), Lyrica (pregabalin) and Zithromax (azithromycin). In 2017, the KSA and Japan also set up a joint group for Saudi-Japan Vision 2030. As part of this, the KSA and Japan will collaborate on areas of medical training and research, etc.
Fabtech Technologies Limited (the "Issuer" or the "Company") was incorporated under the Companies Act, 2013 as a private limited company under the name and style of `Globeroute Ventures Private Limited' pursuant a certificate of incorporation dated October 26, 2018 issued by the Registrar of Companies, Central Registration Centre. Subsequently, pursuant to resolutions passed by our Board of Directors in their meeting held on December 12, 2020 and by our Shareholders in the Extra-Ordinary General meeting held on December 30, 2020, the name of our Company was changed to `Fabtech Technologies Private Limited' and a fresh certificate of incorporation dated January 21, 2021 was issued by the Registrar of Companies, Maharashtra at Mumbai. The name of our Company was changed to expand the scope of services provided by our Company and for securing better overseas prospects, and to give effect to the order dated November 19, 2020 passed by the National Company Law Tribunal having its bench at Mumbai approving inter alia, demerger of the export division of Fabtech Technologies International Private Limited (formerly known as Fabtech Technologies International Limited) into our Company. Further, pursuant to resolutions passed by our Board of Directors in their meeting held on March 27, 2024 and by our Shareholders in the Extra-Ordinary General meeting held on April 3, 2024, our Company was converted into a public limited company, consequent to which its name was changed to `Fabtech Technologies Limited', and a fresh certificate of incorporation dated July 24, 2024, consequent to such conversion was issued by the Registrar of Companies, Central Processing Centre.
Wholesaler and Retailer The Company is a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.